Study to investigate the effects of incretin drugs on depression, quality of life, and eating habits in Type 2 diabetes and obesity

Study to investigate the effects of incretin drugs on depression, quality of life, and eating habits in Type 2 diabetes and obesity - GLP-1 QUEST

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000061705

Enrollment

200

Registered

2026-05-28

Start date

2024-06-26

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Obesity

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. age: 18 years and over 2. new prescriptions in accordance with the following indication criteria for each incretin drugs 3. those who understand the purpose of the study and give their consent. *1: Indication criteria The following indications are to be followed in accordance with the package insert for each drug: 1. persistent GIP/GLP-1 receptor agonist tiruzepatide injection Manjaro subcutaneous injection 2.5mg/5mg/7.5mg/10mg/12.5mg/15mg Ateos, Eli Lilly Japan K.K., approval numbers 30400AMX00420/ 30400AMX00421/ 30400AMX 00422/ 30400AMX00423/ 30400AMX00424/ 30400AMX00425, Revised July 2023 (5th edition) 2. Type 2 diabetes therapeutic agent Semaglutide (genetical recombination), sustained GLP-1 receptor agonist Ozempic subcutaneous injection 2mg, Novo Nordisk Pharma K.K. , Approval No. 23000AMX00443000, Revised: Feb 2024 (Version 3) 3. Oral GLP-1 receptor agonist semaglutide (genetic recombination) Liberusus Tablets 3mg/7mg/14mg, Novo Nordisk Pharma K.K., Approval No. 30200AMX00513000 / 30200AMX00514000/ 30200AMX00515000, Revised February 2024 (4th edition) 4. Obesity treatment Semaglutide (genetical recombination), sustained GLP-1 receptor agonist Ugobi subcutaneous injection 0.25 mg SD/0.5 mg SD/1.0 mg SD/1.7 mg SD/2.4 mg SD, Novo Nordisk Pharma K.K., Approval No. 30500AMX00105000/ 30500AMX00106000/ 30500AMX00107000/ 30500AMX00108000/ 30500AMX00109000, revised Nov 2023 (2nd edition)

Exclusion criteria

Exclusion criteria: 1. those with a history of prescribing incretin (including liraglutide, exenatide, lixisenatide and dulaglutide in addition to the drugs under study. 2. those who have difficulty following the instructions of the principal investigator or a sub-investigator. 3. those who are judged by the principal investigator or a research assistant physician to have difficulty in answering the various questionnaires (depression/anxiety, quality of life, nutritional survey, eating habits). 4. others who are judged by the physician to be undesirable to participate in the research.

Design outcomes

Primary

Measure	Time frame
Changes in treatment response indicators 12 weeks after initiation of incretin treatment.	—

Secondary

Measure	Time frame
Changes in depression and anxiety Changes in quality of life Changes in diet	—

Countries

Japan

Contacts

Public ContactNoriko Satoh-Asahara

National Hospital Organization Kyoto Medical Center Department of Endocrinology, Metabolism and Hypertension Research, Clinical Research

nsatoh@kuhp.kyoto-u.ac.jp075-641-9161

Outcome results